2-(3,5-二甲基-1H-吡唑-4-基)-N-甲基乙胺 | 401632-42-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-(3,5-二甲基-1H-吡唑-4-基)-N-甲基乙胺
• 英文名称: 3,5-dimethyl-4-(2-methylaminoethyl)pyrazole
• 英文别名: UNC10100055A；2-(3,5-dimethyl-1H-pyrazol-4-yl)-N-methylethanamine
• CAS: 401632-42-6
• 化学式: C₈H₁₅N₃
• 分子量: 153.227
• InChiKey: PEYGUQISYVTMGO-UHFFFAOYSA-N

物化性质

• 沸点：
  301.3±37.0 °C(Predicted)
• 密度：
  1.010±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933199090

反应信息

• 作为产物：
  描述：

  3,5-二甲基-4-(2-碘乙基)-1H-吡唑 、 甲胺 以 水 为溶剂， 反应 15.0h， 以82%的产率得到2-(3,5-二甲基-1H-吡唑-4-基)-N-甲基乙胺
  参考文献：
  名称：

  摘要：

  DOI：

  10.1023/a:1012491222562

文献信息

• Pyrimidine derivatives as ALK-5 inhibitors
  申请人：Novartis AG

  公开号：EP1878733A1

  公开（公告）日：2008-01-16

  Compounds of formula I in free or salt or solvate form, where T1, T2, K, Ra and Rb have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  公式I中的化合物以自由形式、盐或溶剂形式存在，其中T1、T2、K、Ra和Rb的含义如规范中所示，可用于治疗由ALK-5和/或ALK-4受体介导的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的过程。
• Benzamide Compounds
  申请人：Gibson Keith Hopkinson

  公开号：US20080293687A1

  公开（公告）日：2008-11-27

  The invention concerns benzamide compounds of Formula (I), wherein R 1a , R 1b , R 1c , R 2 , R 3 , R 4 , m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of histone deacetylase (HDAC).

  这项发明涉及公式（I）的苯甲酰胺化合物，其中R1a、R1b、R1c、R2、R3、R4、m和n具有描述中定义的任意含义；它们的制备过程，含有它们的药物组合物以及它们在制造用作抗增殖剂的药物时的用途，用于预防或治疗对组蛋白去乙酰化酶（HDAC）抑制敏感的肿瘤或其他增殖性疾病。
• 4-DIMETHYLAMINO-PHENYL-SUBSTITUTED NAPHTHYRIDINES, AND USE THEREOF AS MEDICAMENTS
  申请人：Fiegen Dennis

  公开号：US20110263549A1

  公开（公告）日：2011-10-27

  The invention relates to novel substituted naphthyridines of formula 1 as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates, or solvates thereof. In formula 1, R 1 can represent a group A selected from among the group comprising —O—R 3 , —NR 3 R 4 , —CR 3 R 4 R 5 , -(ethyne)-R 3 , —S—R 3 , —SO—R 3 , and SO 2 —R 3 , or R 1 represents a group B selected from among the group comprising: —C 6-10 -aryl;—a five-membered to ten-membered, monocyclic or bicyclic heteroaryl containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heteroaryl is linked to the structure according to formula 1 via a C atom or an N atom;—a three-membered to ten-membered, monocyclic or bicyclic, saturated or partially saturated heterocycle containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heterocycle is linked to the structure according to formula 1 via a C atom or an N atom; and—a 5-membered to 11-membered spiro group which can optionally contain 1, 2, or 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said spiro group is linked to the structure according to formula 1 via a C atom or an N atom, wherein said group B can be optionally substituted as described in claims 1, and R 3 ,R 4 ,R 5 ,R 6 , and m can have the meanings indicated in claim 1. The invention also relates to pharmaceutical compositions containing said compounds.

  该发明涉及具有以下式的新型取代萘啉类化合物，以及其药理学上可接受的盐、对映体异构体、对映体、消旋体、水合物或溶剂合物。在式中，R1可以表示从包括—O—R3、—NR3R4、—CR3R4R5、-(乙炔)-R3、—S—R3、—SO—R3和SO2—R3的群组中选择的A基团，或者R1表示从包括：—C6-10-芳基；—含有1至3个异原子（从N、O和S中独立选择）的五元至十元的单环或双环杂环芳基，其中所述杂环芳基通过碳原子或氮原子与式1中的结构连接；—含有1至3个异原子（从N、O和S中独立选择）的三元至十元的单环或双环、饱和或部分饱和的杂环，其中所述杂环通过碳原子或氮原子与式1中的结构连接；和—一个含有1、2或3个异原子（从N、O和S中独立选择）的五元至十一元的螺环，其中所述螺环通过碳原子或氮原子与式1中的结构连接，其中所述基团B可以按照权利要求中描述的方式被取代，R3、R4、R5、R6和m可以具有权利要求中所示的含义。该发明还涉及含有所述化合物的药物组合物。
• Chemical Compounds
  申请人：Gudmundsson Kristjan

  公开号：US20080045537A1

  公开（公告）日：2008-02-21

  The present invention provides compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind to chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 of a target cell.

  本发明提供了一种化合物，可以通过结合趋化因子受体的方式对目标细胞表现出对HIV感染的保护作用，并影响天然配体或趋化因子与目标细胞的CXCR4等受体的结合。
• CHEMICAL COMPOUNDS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1789045A2

  公开（公告）日：2007-05-30